Literature DB >> 21904660

Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity.

Huiping Zhao1, Bhaskar Reddy Kusuma, Brian S J Blagg.   

Abstract

Structural modifications to the coumarin core and benzamide side chain of novobiocin have successfully transformed the natural product from a selective DNA gyrase inhibitor into a potent inhibitor of the Hsp90 C-terminus. However, no SAR studies have been conducted on the noviose appendage, which represents the rate-limiting synthon in the preparation of analogues. Therefore, a series of sugar mimics and non-sugar derivatives were synthesized and evaluated to identify simplified compounds that exhibit Hsp90 inhibition. Evaluation against two breast cancer cell lines demonstrated that replacement of the stereochemical complex noviose with simplified alkyl amines increased anti-proliferative activity, resulting in novobiocin analogues that manifest IC(50) values in the mid nanomolar range.

Entities:  

Year:  2010        PMID: 21904660      PMCID: PMC3167089          DOI: 10.1021/ml100070r

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  Hsp90 inhibitors in the clinic.

Authors:  S Pacey; U Banerji; I Judson; P Workman
Journal:  Handb Exp Pharmacol       Date:  2006

Review 2.  Hsp90 as a target for drug development.

Authors:  Subhabrata Chaudhury; Timothy R Welch; Brian S J Blagg
Journal:  ChemMedChem       Date:  2006-12       Impact factor: 3.466

3.  A library of noviosylated coumarin analogues.

Authors:  Yung-Tzung Huang; Brian S J Blagg
Journal:  J Org Chem       Date:  2007-03-01       Impact factor: 4.354

4.  A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity.

Authors:  Sabah Ansar; Joseph A Burlison; M Kyle Hadden; Xiao Ming Yu; Kelly E Desino; Jennifer Bean; Len Neckers; Ken L Audus; Mary L Michaelis; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

5.  Synthesis of mono- and dihydroxylated furanoses, pyranoses, and an oxepanose for the preparation of natural product analogue libraries.

Authors:  Xiao Ming Yu; Huijong Han; Brian S J Blagg
Journal:  J Org Chem       Date:  2005-07-08       Impact factor: 4.354

6.  Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.

Authors:  D C Hooper; J S Wolfson; G L McHugh; M B Winters; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.

Authors:  Yuanming Lu; Sabah Ansar; Mary L Michaelis; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2008-12-25       Impact factor: 3.641

Review 8.  Hsp90: a novel target for the disruption of multiple signaling cascades.

Authors:  Stephanie C Bishop; Joseph A Burlison; Brian S J Blagg
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

9.  KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.

Authors:  Shary N Shelton; Mary E Shawgo; Shawna B Matthews; Yuanming Lu; Alison C Donnelly; Kristen Szabla; Mehmet Tanol; George A Vielhauer; Roger A Rajewski; Robert L Matts; Brian S J Blagg; John D Robertson
Journal:  Mol Pharmacol       Date:  2009-09-09       Impact factor: 4.436

10.  Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.

Authors:  Joseph A Burlison; Len Neckers; Andrew B Smith; Anthony Maxwell; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

View more
  22 in total

1.  Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor.

Authors:  Anuj Khandelwal; Jessica A Hall; Brian S J Blagg
Journal:  J Org Chem       Date:  2013-08-01       Impact factor: 4.354

Review 2.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

3.  Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

4.  Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.

Authors:  Huiping Zhao; Mercy Anyika; Antwan Girgis; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2014-05-16       Impact factor: 2.823

5.  Development of radamide analogs as Grp94 inhibitors.

Authors:  Aaron Muth; Vincent Crowley; Anuj Khandelwal; Sanket Mishra; Jinbo Zhao; Jessica Hall; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-06-12       Impact factor: 3.641

6.  Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.

Authors:  Gaurav Garg; Leah K Forsberg; Huiping Zhao; Brian S J Blagg
Journal:  Chemistry       Date:  2017-11-03       Impact factor: 5.236

7.  Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.

Authors:  Leah K Forsberg; Mercy Anyika; Zhenyuan You; Sean Emery; Mason McMullen; Rick T Dobrowsky; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2017-10-18       Impact factor: 6.514

8.  Exploiting polarity and chirality to probe the Hsp90 C-terminus.

Authors:  Leah K Forsberg; Rachel E Davis; Virangika K Wimalasena; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2018-04-13       Impact factor: 3.641

9.  Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.

Authors:  Bhaskar Reddy Kusuma; Anuj Khandelwal; Wen Gu; Douglas Brown; Weiya Liu; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

10.  3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition.

Authors:  Huiping Zhao; Bin Yan; Laura B Peterson; Brian S J Blagg
Journal:  ACS Med Chem Lett       Date:  2012-02-26       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.